What changed in the ORKA analyst rating on March 13, 2026?

BTIG reiterated a **Buy** on **March 13, 2026** and kept a **$73** price target. The ORKA analyst rating therefore remained unchanged but positive, and the stock rose roughly **5.74%** on the news.

Does the maintained Buy mean ORKA will reach the $73 target?

A maintained Buy signals analyst confidence, not certainty. Price targets reflect scenarios and assumptions. Investors should combine the ORKA analyst rating with clinical results and financials before acting.

Who covered Oruka Therapeutics in this update?

The single firm in the provided dataset is **BTIG**, which issued the March 13, 2026 note. No downgrades were reported in this set, and BTIG remains the visible analyst voice here.

How does Meyka AI view ORKA after the rating action?

Meyka AI rates ORKA with a grade of **B**. This grade uses S&P 500 comparison, sector performance, growth metrics, key financials, and analyst consensus, including the ORKA analyst rating from BTIG.

Analyst Ratings

BTIG Maintains Buy on Oruka Therapeutics (ORKA) March 13, 2026

ByHuzaifa Zahoor March 16, 2026March 16, 2026

On March 13, 2026, BTIG maintained a Buy on Oruka Therapeutics, Inc. (ORKA). The ORKA analyst rating stays positive after BTIG cited commercial precedents for ORKA-001/2. BTIG also kept a $73 price target, according to coverage published that morning. The stock moved 5.74% higher, equal to $2.17, after the reiteration. Market capitalization stands at $1,498,031,760. Meyka AI rates ORKA with a grade of B. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.